In a study presented at the on-going ESHRE conference in Istanbul,
Vitrolife's (STO:VITR) patent protected medium EmbryoGlue® has once
again been proven to increase both implantation and pregnancy rates,
regardless of hormone stimulation of the endometrium or not.
Dr. Nakagawa from Japan, who performed the study, investigated whether
the preparation method of the endometrium, the lining of the uterus,
before transfer had an effect on pregnancy rate or not. The prospective
randomized study included 203 patients under the age of 40, all with
four or more previous implantation failures. 101 of the women had embryo
transfer in a natural ovulation cycle, and 102 women were prepared by
hormone replacement cycle. Patients in each group were allocated to
transfer with either EmbryoGlue® or a transfer medium with no hyaluronan.
The study showed that the pregnancy rate increased significantly for the
group receiving transfer in EmbryoGlue®. In the group with natural
cycles it increased from 10% till 31.4% and in the group receiving
transfer in a hormone stimulated cycle from 15.7% to 41.2%
"I am very happy to present these data, showing that women with many
previous implantation failures have a chance of becoming parents," says
EmbryoGlue® is a medium patent protected by Vitrolife, enriched with
hyaluronan, a natural substance abundant in all tissues in the body. It
has a unique combination of a high concentration of hyaluronan and
recombinant albumin. EmbryoGlue® is used when transferring embryos into
the woman as the final step of an IVF treatment.
The use of EmbryoGlue® for embryo transfer has been analysed in numerous
studies, showing an increased treatment success independent of patient
age, day of transfer and now also preparation of the endometrium.